AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 11 min read$CRSP

Patel Naimish sold $211K of CRSP

Patel Naimish (Chief Medical Officer) sold 3,786 shares of CRISPR Therapeutics AG (CRSP) at $55.62 ($0.21M total) on 2026-05-29.

Original reporting
SEC EDGAR · Patel Naimish
Published Jun 1, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

This provides a datapoint on insider behavior but does not introduce new clinical, regulatory, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to be a primary driver of price.

03

What to watch

No 10b5-1 plan is cited, but the article provides no reason for the sale, tax context, or whether other insiders executed offsetting trades.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-01 (sale dated 2026-05-29).

Background

The article is an SEC Form 4 insider transaction disclosure for CRISPR Therapeutics (CRSP).

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

CRSP’s CMO Patel Naimish sold 3,786 shares in an open-market transaction disclosed via SEC Form 4 on 2026-05-29.

Expected impact

Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an officer open-market sale with no stated link to new clinical/regulatory or financial developments; 10b5-1 plan is explicitly marked as not pre-arranged, but insider sales alone rarely drive durable repricing without corroborating news.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.

Regional

None indicated beyond US-listed biotech sentiment.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the small absolute size versus typical insider holdings.

Key entities

  • issuer
    CRISPR Therapeutics AG

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Patel Naimish

    Chief Medical Officer who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min
AUG 4
$CRSPMed

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.

zacks.com6 min